The high cost of Gilead Science's hepatitis C drug Sovaldi is causing Medicaid to come up with new ways of handling drug costs, according to Matt Salo, executive director of the National Association of Medicaid Directors.
The high cost of Gilead Science’s hepatitis C drug Sovaldi is causing Medicaid to come up with new ways of handling such an expensive drug, according to Matt Salo, executive director of the National Association of Medicaid Directors.
He discussed high-cost specialty drugs and their effect on Medicaid at the America’s Health Insurance Plans National Conferences on Medicare and Medicaid, and Dual Eligibles Summit in Washington, DC, from September 28 to October 2.
“[Sovaldi is] great from a public health perspective; but when you multiply large unit cost times a very large number of people, this drug alone has the potential of doubling Medicaid’s pharmacy spend,” Mr Salo said.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen